last I saw: In 2016, Amarantus disposed of its wholly-owned diagnostics subsidiary, namely, Amarantus Diagnostics, Inc., to Avant Diagnostics, Inc. ("Avant"
(OTCQB: AVDX). Avant, in turn, paid an aggregate consideration of 80,000,000 shares of its common stock and a US$50,000 convertible promissory note for the acquisition